New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites

被引：3
作者：
Li, Huanyu [1 ]
Pan, Meng [2 ]
Li, Yifan [1 ]
Cui, Manli [3 ]
Zhang, Mingxin [3 ]
机构：
[1] Shaanxi Univ Chinese Med, Clin Med Coll 2, Xianyang 712046, Shaanxi, Peoples R China
[2] Shaanxi Univ Chinese Med, Coll Basic Med Sci, Xianyang 712046, Shaanxi, Peoples R China
[3] Xian Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Xian 710077, Shaanxi, Peoples R China
来源：
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL | 2025年 / 27卷
关键词：
Gut microbiota; Microbial metabolites; Ulcerative colitis; Microcapsules; Nanoparticles; Prebiotics; Probiotics; FMT; INFLAMMATORY BOWEL DISEASES; CHAIN FATTY-ACIDS; BILE-ACIDS; GERM-FREE; TRYPTOPHAN-METABOLISM; FECAL TRANSPLANTATION; BIFIDOBACTERIUM-BREVE; BACTERIAL METABOLITES; RECEPTOR; REMISSION;
D O I：
10.1016/j.csbj.2025.05.006
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ulcerative colitis (UC) is one of the most common and difficult-to-treat inflammatory diseases Currently, the standard of care includes immunological modulation and anti-inflammatory medication to alleviate symptoms; however, these treatments are associated with several side effects. As a result, developing novel, safe, and effective treatment strategies is crucial. The gut microbiota and its influence on the onset and progression of UC through their regulation of immunity, barrier integrity, and homeostasis, serves as a promising target for UC therapy. In this review, we explore the pathological changes that take place in UC along with the role of gut microbiota and its metabolites in disease progression and modulation. Additionally, we offer a thorough description of novel UC treatment approaches that focus on altering the gut microbiota and its metabolites. These protocols include FMT, probiotics, prebiotics, and micro/nanoparticles. The ultimate goal is to offer a theoretical basis for the advancement of innovative therapeutic strategies for UC.
引用
收藏
页码：1850 / 1863
页数：14
相关论文
共 198 条
[1]  
ABRAMS GD, 1963, LAB INVEST, V12, P355
[2]   An insight into gut microbiota and its functionalities [J].
Adak, Atanu ;
Khan, Mojibur R. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (03) :473-493
[3]   Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease [J].
Agus, Allison ;
Planchais, Julien ;
Sokol, Harry .
CELL HOST & MICROBE, 2018, 23 (06) :716-724
[4]   Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases [J].
Akutko, Katarzyna ;
Stawarski, Andrzej .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (11)
[5]   Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor [J].
Alexeev, Erica E. ;
Lanis, Jordi M. ;
Kao, Daniel J. ;
Campbell, Eric L. ;
Kelly, Caleb J. ;
Battista, Kayla D. ;
Gerich, Mark E. ;
Jenkins, Brittany R. ;
Walk, Seth T. ;
Kominsky, Douglas J. ;
Colgan, Sean P. .
AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (05) :1183-1194
[6]   The Therapeutic Role of Short-Chain Fatty Acids Mediated Very Low-Calorie Ketogenic Diet-Gut Microbiota Relationships in Paediatric Inflammatory Bowel Diseases [J].
Alsharairi, Naser A. .
NUTRIENTS, 2022, 14 (19)
[7]  
Ariaee Amin, 2024, eGastroenterology, V2, pe100055, DOI 10.1136/egastro-2023-100055
[8]   Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation [J].
Arpaia, Nicholas ;
Campbell, Clarissa ;
Fan, Xiying ;
Dikiy, Stanislav ;
van der Veeken, Joris ;
deRoos, Paul ;
Liu, Hui ;
Cross, Justin R. ;
Pfeffer, Klaus ;
Coffer, Paul J. ;
Rudensky, Alexander Y. .
NATURE, 2013, 504 (7480) :451-+
[9]   Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination [J].
Augustine, Robin ;
Ashkenazi, Dana Levin ;
Arzi, Roni Sverdlov ;
Zlobin, Vita ;
Shofti, Rona ;
Sosnik, Alejandro .
ACTA BIOMATERIALIA, 2018, 74 :344-359
[10]   Glucocorticoid resistance in inflammatory diseases [J].
Barnes, Peter J. ;
Adcock, Ion M. .
LANCET, 2009, 373 (9678) :1905-1917
12345678910